The role of autophagy-related genes in the evaluation of therapeutic effect of ET regimen neoadjuvant chemotherapy in breast cancer
10.3969/j.issn.1671-8348.2015.03.017
- VernacularTitle:自噬相关基因在乳腺癌ET方案新辅助化疗疗效预测中的作用
- Author:
Jun LI
;
Xiaoyu LIU
;
Geli JIANG
;
Xiaodong HE
;
Yong CAO
;
Xin ZHOU
;
Xiaohua ZENG
- Publication Type:Journal Article
- Keywords:
breast neoplasms;
autophagy;
chemotherapy,adjuvant;
ET regimen;
Atg3;
Beclin1
- From:
Chongqing Medicine
2015;(3):337-339,342
- CountryChina
- Language:Chinese
-
Abstract:
Objective To identify the role of autophagy‐related genes in prediction of therapeutic effect of ET regimen neoadju‐vant chemotherapy in breast cancer .Methods Breast cancer tissues were retrospectively collected from 41 cases of breast cancer pa‐tients that treated by ET regimen neoadjuvant chemotherapy with different therapeutic effects .Expressions of Atg3 and Beclin1 ,and the autophagy‐related genes ,were detected by Western blot ,Real‐time PCR and immunohistochemistry in these tissues to observe their expressions before neoadjuvant chemotherapy .Statistical test was used to analyze the relationship between Atg3 ,Beclin1 ex‐pressions and therapeutic effects of ET regimen neoadjuvant chemotherapy .Results Western blot ,Real‐time PCR and immunohis‐tochemistry revealed that expressions of Atg3 and Beclin1 were up‐regulated in 24 breast cancer tissues before neoadjuvant chemo‐therapy ,including 23 cases of complete response(CR) or partial response (PR) (95 .8% ) and 1 case of progressive disease (PD) . Atg3 and Beclin1 were not expressed or lowly expressed in the other 17 cases ,including 3 cases of CR or PR (17 .6% ) and 14 cases of no change and PD .The effective rate of ET regimen neoadjuvant chemotherapy in breast cancer patients with over expression of Atg3 and Beclin1 was significantly higher than those with low expression or without expression of Atg3 and Beclin1 (P<0 .05) . Conclusion Over expression of Atg3 and Beclin1 could be new indicators for therapeutic effect of ET regimen neoadjuvant chemo‐therapy in breast cancer .
